Anti-Claudin 18.2 Antibody-drug Conjugate JS107 clinical trials
Also written JS107.
How each study uses Anti-Claudin 18.2 Antibody-drug Conjugate JS107 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-Claudin 18.2 Antibody-drug Conjugate JS107 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JS107
- 2
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2025 | 1 |
Who runs them
Industry 0 · Other 3
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Anti-Claudin 18.2 Antibody-drug Conjugate JS107, phase 3 first.
- Oct 2027JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.Phase 3 · Shanghai Junshi Bioscience Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-Claudin 18.2 Antibody-drug Conjugate JS107 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.RecruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07284134Written as JS107 for InjectionHow we know
- A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT05502393Written as JS107How we know
- A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic CancerTerminatedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT05657418Written as JS107How we know